Wells Fargo Cuts Johnson & Johnson (JNJ) Price Target to $275

Wells Fargo has reiterated its Overweight rating on Johnson & Johnson with a new price target of $275, a 7.71% upside from the current price.

By EarningsIQ Research Desk · Published Oct 15, 2026, 9:18 PM EDT · Updated Oct 16, 2026, 1:55 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Wells Fargo cut its price target on Johnson & Johnson ($JNJ) to $275 from $282 on October 14, 2026, and rates the stock "Overweight".

Since the rating, $JNJ is up 0.7% to date (from the $253.91 close on Oct 14, 2026).

JNJ Johnson & Johnson

$255.56 +25.23% year to date

Daily close · Oct 16, 2026

Key Points

On October 14, 2026, Wells Fargo reiterated its Overweight rating on Johnson & Johnson, setting a price target of $275, down from $282.
Wells Fargo's $275 price target implies 7.71% upside from Johnson & Johnson's ($JNJ) current $255.31 share price.
As of October 16, 2026, Johnson & Johnson's stock traded recently around $255.31, which is below the new target by about 7.2%.
The stock is currently below its 50-day moving average and 9.2% under its 52-week high of $281.07.

Get $JNJ trade alerts by text

We text you when insiders, Congress or big funds trade $JNJ. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Johnson & Johnson alert may contain errors. Disclosures

Wells Fargo has reiterated its Overweight rating on Johnson & Johnson (NYSE: JNJ) as of October 14, 2026. The firm set a price target of $275, which is a decrease from the previous target of $282. This change reflects the firm's ongoing confidence in the company despite the adjusted target.

Other Institutional Activity in Johnson & Johnson

Several other institutional investors have also adjusted their positions in Johnson & Johnson. Blackrock Inc. reduced its holdings by 1,280,271 shares, ending with 212,098,264 shares worth about $54.2 billion. Vanguard Capital Management LLC grew its stake by 626,400 shares, bringing its total to 157,226,374 shares valued at approximately $40.2 billion. State Street Corporation added 293,661 shares, increasing its total to 133,776,025 shares worth about $34.2 billion.

Johnson & Johnson Stock Up 0.6%

Currently, Johnson & Johnson's stock trades around $255.31, which is below its 50-day moving average of $265.26 by about 3.8%. It's also 9.2% below its 52-week high of $281.07, indicating a challenging market position relative to its recent performance.

12-month forecast

$JNJ price target

Johnson & Johnson daily closes and this analyst's $275 target. Not advice.

Recent Earnings

In its latest earnings report, Johnson & Johnson reported trailing twelve-month revenue of approximately $99.3 billion, with a net margin of 16.2%. The company has a P/E ratio of about 38.4. Its next earnings date is scheduled for January 26, 2027.

Insider Buying and Selling at Johnson & Johnson

Recent insider transactions show significant selling activity. On August 6, 2026, Elizabeth Forminard, an officer, sold 15,918 shares valued at approximately $4.1 million. CEO Joaquin Duato sold 123,291 shares on August 13, 2026, worth about $32.2 million. Jennifer L. Taubert sold 15,000 shares at an average price of $263.36 on August 17, 2026, totaling around $3.95 million. Timothy Schmid sold 33,597 shares at an average price of $274.74 on September 2, 2026, valued at about $9.2 million.

Analysts Set New Price Targets

On October 14, 2026, Wells Fargo maintained its Overweight rating on Johnson & Johnson with a target price of $275. RBC Capital also maintained its Outperform rating with a target of $280. Meanwhile, Leerink Partners kept its Outperform rating but lowered its target to $272.

About Johnson & Johnson

Johnson & Johnson, based in New Brunswick, NJ, is a major player in the healthcare sector. The company focuses on research, development, and manufacturing of a wide range of healthcare products, operating through its Innovative Medicine and MedTech segments.

Bottom Line

Investors should keep an eye on Johnson & Johnson as it approaches its next earnings date on January 26, 2027. With the stock trading below the new analyst target, market movements will be important to watch in the coming weeks.